Loading
Instead of blocking a cancer protein, add a chemical off-switch to its gene so the cell stops making it. Early versions of this tool are being tested in other diseases.
CRISPR-based epigenetic silencers (CRISPRoff and related systems) place heritable DNA methylation and repressive marks at a promoter without cutting DNA. Delivered by lipid nanoparticles, this could durably silence an amplified or overexpressed but undruggable oncogene. Epigenetic editing has entered clinical development for a liver target, establishing delivery and durability precedent in humans.
Shares Drugging the 'undruggable' cancer targets, Epigenetic drugs (HDAC, DNMT, EZH2, IDH, menin, BET), The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, CRISPR functional genomics, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, CRISPR functional genomics, The undruggable drivers.
Shares Drugging the 'undruggable' cancer targets, CRISPR functional genomics, The undruggable drivers.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/